EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
King Hussein Research Award22/01/2021
HRH Princess Ghida Talal, Chairperson of the King Hussein Cancer Foundation and Center, launched the King Hussein Cancer Research Award to honor Arab leaders in cancer research who have made outstanding achievements in the fields of prevention, early detection, diagnosis, treatment, and palliative care. Increased scientific research will lead us to a stronger future of confronting cancer in the Middle East region. We encourage you to visit the Award website.
View the website
Highlighting NCI Support for Global Health Collaboration and Equity at London Global Cancer Week21/01/2021
Despite the ongoing pandemic, the NCI Center for Global Health (NCI/CGH) hosted a webinar at London Global Cancer Week in November 2020. “International Collaboration to Advance Global Cancer Research: The US National Cancer Institute Perspective” showcased NCI-funded research training and collaborations, along with lessons learned and recommendations for building international partnerships to advance global cancer research and control. Consult a summary of the interventions, including a presentation from Dr Partha Basu on building a team to implement affordable technology to treat cervical cancer in Zambia. View the website
New publication: Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study19/01/2021
In a new study, scientists from the IARC Screening group and partners in the Indian HPV Vaccine Study Group assessed type-specific prevalence, natural history, and potential determinants of human papillomavirus (HPV) infection in 1484 unvaccinated married women aged 18–23 years. The study was published in the journal PLoS One. This study clearly shows that young Indian women are at high risk of being infected with HPV, especially HPV16, the most oncogenic type. This is a compelling reason for the Government of India to introduce HPV vaccination in the country, which currently accounts for one fifth of the global burden of cervical cancer.
View the IARC news and view the article
New publication: Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India18/01/2021
In this publication, the authors presented the case studies from Bangladesh and India, and highlighted that program organization, rather than the choice of a screening test, determines the success rate of cervical cancer screening.
View the article
New publication: Risk-Based Selection of Individuals for Oral Cancer Screening18/01/2021
This publication based on the Kerala Oral Cancer Randomized Controlled Trial conducted by scientists from IARC in collaboration with Regional Cancer Center, Thiruvananthapuram in India and US National Institutes of Health (NIH)/National Cancer Institute, provides proof of principle for resource-efficient, risk-based oral cancer screening through a risk-based reanalysis of the trial outcomes. In the Kerala trial, the efficacy of oral cancer screening was greatest in individuals at highest oral cancer risk. The authors observed that screening 100% of the population would result in a 27% reduction in mortality from oral cancer whereas screening 22% of the population composed of ever-tobacco and/or ever-alcohol users at highest risk would resulted in 20% oral cancer mortality reduction. These results provide proof of principle that risk-based oral cancer screening could substantially enhance the efficiency of screening programs. View the article.
CanScreen5 Train the Trainers - Africa Region Live session 515/01/2021
Continuation of the CanScreen5 Train the Trainers African course, with participants from 17 African countries. The CanScreen5 Train the Trainers course aims to contribute to the creation of a dynamic global network of master trainers capable of training health care providers on cancer screening program monitoring, evaluation and quality improvement and also to contribute data to the CanScreen5 project. Today, Dr R. Sankaranarayanan, IARC Senior Visiting Scientist, Former IARC Head of the Section of Early Detection and Prevention and Special Advisor on Cancer Control, addressed a key not lecture about the pragmatic implementation, monitoring and evaluation of early detection programmes. Learn more about the CanScreen5 platform.
Virtual meeting: Cancer screening webinar14/01/2021
Dr Partha Basu, Head of Screening Group, Early Detection & Prevention Section at the International Agency for Research on Cancer participated to this Cancer screening webinar organized by Innovative partnership for action against cancer (IPAAC) co-funded by the Health Programme of the European Union. He discussed about Cancer screening in Europe - shifting paradigms.
Video: CanScreen5 website tour11/01/2021
New publication: Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study08/01/2021
In this study, the authors systematically evaluated the prevalence and natural history of HPV infection over a median period of nearly 4 years in a young sexually active cohort of women. More than one third of the women were infected over time with any of the 21 HPV types; HPV 16 being most frequently detected followed by HPV 31, 58 and 56 in that order. Over 90% of the infected women cleared the infection by 36 months irrespective of the HPV type. The clearance rate was significantly higher in the initial months of infection–a phenomenon well-documented by previous studies. This might also partly explain why women with a 2–3 year gap between marriage and first cervical cell collection had a reduced risk of HPV infection as they may have had time to clear the infection. Our study clearly shows that the Indian women are at high risk of being infected with HPV, especially HPV types 16 and 18.
View the article